Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009 Global Health Ventures Inc.: Global Health Ventures to Begin Testing of its Super Stimulus Sublingual Film at the University of
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 31, 2009) - Global Health Ventures Inc. (OTCBB:GHLV), a Specialty Pharma is pleased to announce the start of a series of pharmaceutical tests on its "Super Stimulus" sublingual formulation product under the code name GLV-0905. The product is placed under the tongue which allows for the rapid and highly efficient absorption. The Pharmaceutical School of the University of British Columbia in Vancouver is famous for the top level testing and new formulations of drugs, biological and consumer products. The Company's tests will examine product stability, taste, absorption rates and efficiency and are a key part of the final stage of prototype preparation.
About GHLV-0905
GHLV-0905 is the Company's active energy product designed for sport, work, study, and general daily life. Users will put a small piece of the film under their tongue and get a quick, efficient, long lasting boost of energy without the sugar or calories normally associated with energy drinks. The Super Stimulus product is scheduled to be ready for marketing in late 2009/early 2010. Demand for energy supplements and in particular products that work fast and contain no sugar or calories is extremely large and growing quickly. The Company has already received invitations for co-marketing from several direct marketers and on-line merchants. Management expect the product to be well-received and to provide the Company access to a wide and lucrative market.
About Global Health Ventures
Global Health Ventures (the "Company) is a specialty pharma with focus on OTC market. The Company has a new proprietary platform technology that delivers many approved drugs via the sublingual (under the tongue) route. This unique method delivers low dose drugs directly to the blood stream, bypassing all the side effects of digestive and liver system breakdowns, while maintaining product efficacy. The Company currently has five products in late stage of development and several more under development.
Safe Harbour Statement
This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further the risk involves the ability of the Company to raise capital to fund its operations and the capital requirements development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.
